SY 162

Drug Profile

SY 162

Alternative Names: Recombinant staphylokinase variant - ThromboGenics

Latest Information Update: 22 May 2007

Price : $50

At a glance

  • Originator University of Leuven
  • Developer ThromboGenics
  • Class Plasminogen activator enzymes; Recombinant proteins; Thrombolytics
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Peripheral arterial occlusive disorders; Venous thrombosis

Most Recent Events

  • 28 Apr 2004 This compound is still in active development
  • 09 May 2001 New profile
  • 09 May 2001 Phase-II clinical trials for Venous thrombosis in Belgium (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top